Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
NEJM 352:2379-2388,2439, Petersen,R.C.,et al, 2005
Anticoagulants in the Oldest Old with Recent Stroke and Atrial Fibrillation
Ann Neurol 91:78-88, Polymeris, A.A.,et al, 2022
Economic Evaluation of Andexanet Versus Prothrombin Complex Concentrate for Reversal of Factor Xa-Associated Intracranial Hemorrhage
Stroke 52:1390-1397, Micieli, A.,et al, 2021
Left Ventricular Dysfunction Among Patients with Embolic Stroke of Undetermined Source and the Effect of Rivaroxaban vs Aspirin
JAMA Neurol 78:1454-1460, Merkler, A.E.,et al, 2021
Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer
NEJM 382:1599-1607,1650, Agnelli, G.,et al, 2020
Stroke Reperfusion Therapy Following Dabigatran Reversal with Idarucizumab in a National Cohort
Neurol 94:e1968-e1972, Barber, P.A.,et al, 2020
Contemporary Reversal of Oral Anticoagulation in Intracerebral Hemorrhage
Stroke 50:529-536, Bower, M.M.,et al, 2019
Clinical Effectiveness of Direct Oral Anticoagulations vs Warfarin in Older Patients with Atrial Fibrillation and Ischemic Stroke
JAMA Neurol 76:1192-1202, Xian, Y.,et al, 2019
Andexxa-An Antidote for Apixaban and Rivaroxaban
JAMA 320:399-400, , 2018
Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation
NEJM 376:1627-1636, Calkins, H.,et al, 2017
Idarucizumab for Dabigatran Reversal - Full Cohort Analysis
NEJM 377:431-441, Pollack, C.V.,et al, 2017
Oral Anticoagulants for Prevention of Stroke in Atrial Fibrillation: Systematic Review, Network Meta-Analysis, and Cost Effectiveness Analysis
BMJ 359:J5058, Lopez-Lopez, J.A.,et al, 2017
Which Oral Anticoagulation for Atrial Fibrillation?
JAMA 315:2117-2118, The Medical Letter, 2016
Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients
Stroke 47:1555-1561, Shah, A.,et al, 2016
Outcomes with Edoxaban Versus Warfarin in Patients with Previous Cerebrovascular Events
Stroke 47:2075-2082, Rost, N.S.,et al, 2016
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors
NEJM 375:1131-1141,1185, Connolly, S.J.,et al, 2016
Stroke Outcomes with use of Antithrombotics within 24 hours after Recanalization Treatment
Neurol 87:996-1002, Jeong, H.G.,et al, 2016
Rates of Ischemic Stroke During Warfarin Treatment for Atrial Fibrillation
Stroke 46:1120-1122, Tung, J.M.,et al, 2015
Efficacy of Folic Acid Therapy in Primary Prevention of Stroke Among Adults with Hypertension in China
JAMA 313:1325-1335,1321, Huo, Y.,et al, 2015
Stroke Prevention in Atrial Fibrillation
JAMA 313:1950-1962, Lip, G.Y.H. & Lane, D.A., 2015
Idarucizumab for Dabigatran Reversal
NEJM 373:511-520, Pollack, C.V.,et al, 2015
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation
NEJM 373:823-833, Douketis,J.D.,et al, 2015
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity
NEJM 373:2413-2424,2471, Siegal, D.M.,et al, 2015
Endovascular Treatment for Acute Ischemic Stroke in the Setting of Anticoagulation
Stroke 46:3536-3539, Rebello, L.C.,et al, 2015
FDA Approves Praxbind, the First Reversal Agent for the Anticoagulant Pradaxa
JAMA 314:2227, , 2015
Summary of Evidence-Based Guideline Update: Prevention of Stroke in Nonvalvular Atrial Fibrillation
Neurol 82:716-724, Culebras, A.,et al, 2014
Comparison of the Efficacy and Safety of New Oral Anticoagulants with Warfarin in Patients with Atrial Fibrillation: A Meta-Analysis of Randomised Trials
Lancet 383:955-962,931, Ruff, C.T.,et al, 2014
Factor Xa Inhibitors vs Warfarin for Preventing Stroke and Thromboembolism in Patients with Atrial Fibrillation
JAMA 311:1150-1151, Bruins Slot, K.M.H. & Berge, E., 2014
Novel Factor Xa Inhibitor for the Treatment of Cerebral Venous and Sinus Thrombosis
Stroke 45:2469-2471, Geisbusch, C.,et al, 2014
Cerebrovascular Events in 21 105 Patients with Atrial Fibrillation Randomized to Edoxaban Versus Warfarin
Stroke 45:2372-2378, Giugliano, R.P.,et al, 2014
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
NEJM 368:1092-1100,1152, Carroll, J.D.,et al, 2013
Percutaneous Closure of Patent Foramen Ovale in Cryptogenic Embolism
NEJM 368:1083-1091,1152, Meier, B.,et al, 2013
Faxtor Xa Inhibitors Versus Vitamin K Antagonists for Preventing Cerebral or Systemic Embolism in Patients with Atrial Fibrillation
Stroke 44:e165-e167, Bruins, K.M.H., & Berge, E., 2013
Edoxaban Versus Warfarin in Patients with Atrial Fibrillation
NEJM 369:2093-2104, Giugliano, R.P.,et al, 2013
Using Dabigatran in Patients with Stroke A Practical Guide for Clinicians
Stroke 43:271-279, Alberts, M.J.,et al, 2012
New Antithrombotic Drugs for Atrial Fibrillation: Caution is Needed
Lancet 379:e24, Bell,S.,et al, 2012
Patent Foramen Ovale Closure and Medical Treatments for Secondary Stroke Prevention
Stroke 43:422-431, Kitsios,G.D.,et al, 2012
Evidence-based Guideline Update: NSAIDs and Other Complementary Treatments for Episodic Migraine Prevention in Adults
Neurol 78:1346-1353, Holland,S.,et al, 2012
Antiplatelets vs Anticoagulation for Dissection
Neurol 79:686-689, Kennedy, F.,et al, 2012
Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomized controlled trial
Lancet 380:1749-1758, Lopes, R.,et al, 2012
Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation
Stroke 43:3442-3453, Furie, K.,et al, 2012
Nonvitamin K-Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack
Stroke 43:3298-3304, Ntaios, G.,et al, 2012
Apixaban in Patients With Atrial Fibrillation
NEJM 364:806-817, Connolly,S.J.,et al, 2011
Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data
Pharmacol Ther 129:185-194, Terry, K.W.,et al, 2011
Apixaban in Atrial Fibrillation From Bleeding Cows to 21st Century Medicinal Chemistry
Stroke 42:2376-2378, Cucchiara, B.L.,et al, 2011
Rivaroxaban versus Warfarin in Nonvavular Atrial Fibrillation
NEJM 365:883-891, 952, Patel, M.R.,et al, 2011
Apixaban versus Warfarin in Patients with Atrial Fibrillation
NEJM 365:981-992,1052, Granger, C.B.,et al, 2011
Dabigatran Challenges Warfarins Superiority for Stroke Prevention in Atrial Fibrillation
Stroke 41:1307-1309, Schwartz,N.E. &Albers,G.W., 2010
Point-of-Care Reversal Treatment in Phenprocoumon-Related Intracerebral Hemorrhage
Ann Neurol 67:788-793, Rizos,T., et al, 2010